Research stack

Tirzepatide + Tesamorelin Recomposition Protocol

Dual-incretin weight reduction paired with GHRH-driven visceral-fat and lean-mass support.

Component peptides

A dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that has been characterised in metabolic and body-weight research at reference doses of 2.5–15 mg per week.

Tesamorelin

A stabilised GHRH analog carrying a trans-3-hexenoyl group at the N-terminus, protecting against dipeptidyl-peptidase-IV cleavage. FDA-approved in 2010 as Egrifta for reduction of excess visceral abdominal fat in HIV-associated lipodystrophy.

Goal

Dual-incretin weight reduction paired with GHRH-driven visceral-fat and lean-mass support.

Peptides

Tirzepatide, Tesamorelin

Why it works

GIP/GLP-1 co-agonism drives total weight loss while GHRH-analog signalling restores pulsatile GH to bias fat loss toward visceral depots and preserve lean mass.

How to use

Tirzepatide — 2.5 mg weekly sc for 4 weeks, then escalate by 2.5 mg every 4 weeks to target 10-15 mg weekly.
Tesamorelin — 2 mg once daily subcutaneous, evening.

Last updated: 2026-09-15

Component peptides	Tirzepatide + Tesamorelin
Duration reported	26 weeks
Cycle pattern	26 weeks, tirzepatide escalated continuously, tesamorelin continuous
Difficulty	advanced
Regulatory status	Research use only. None of these compounds is FDA-approved for combined use described.

Peptide Codex Assistant

Research-literature companion

Hello. Ask me about a peptide, a stack, or a research protocol on Peptide Codex.

0 / 20 questions used todayResearch use only. Not medical advice.